Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115778 · ClinicalTrials.gov registry record · Phase 2
Intravenous Immunoglobulin (IVIG) in Lung Transplantation
A Phase 2 study of Lung Transplantation and Hypogammaglobulinemia, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00115778 is a Phase 2 study of Lung Transplantation and Hypogammaglobulinemia that has completed, run by Columbia University. The registered enrollment target is 11 participants, below the 335-participant average among 12 other Lung Transplantation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00115778, a Phase 2 study of Lung Transplantation and Hypogammaglobulinemia, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG IVIG
Study Locations (1)
New York
- New York Presbyterian Hospital Lung Transplant Program - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115778
The ClinicalTrials.gov registry entry for NCT00115778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 335-participant average among 12 other Lung Transplantation trials with a reported enrollment target (97% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00115778 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00115778 about?
NCT00115778 is a clinical study titled "Intravenous Immunoglobulin (IVIG) in Lung Transplantation". The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
What is the current status of trial NCT00115778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2005-06. Estimated completion is 2010-08.
What conditions does trial NCT00115778 study?
This clinical trial studies the following conditions: Lung Transplantation, Hypogammaglobulinemia.
What interventions are being tested in trial NCT00115778?
The interventions under investigation include: Placebo (OTHER), IVIG (DRUG).
Who is sponsoring clinical trial NCT00115778?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115778 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
RECRUITING · Phase 2
-
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
RECRUITING · Phase 2
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
Trifecta-Lung cfDNA-MMDx Study
RECRUITING
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
-
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.